Cyclo Net Income from 2010 to 2025
| CYTHW Stock | USD 0.28 0.04 16.67% |
Net Loss | First Reported 2000-09-30 | Previous Quarter -6 M | Current Value -8.8 M | Quarterly Volatility 16.5 B |
Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 21.1 K, Interest Expense of 181.7 K or Total Revenue of 1 M, as well as many indicators such as Price To Sales Ratio of 22.79, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.
Cyclo | Net Income |
Latest Cyclo Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Cyclo Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cyclo Therapeutics financial statement analysis. It represents the amount of money remaining after all of Cyclo Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cyclo Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (20.06 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cyclo Net Income Regression Statistics
| Arithmetic Mean | (7,326,610) | |
| Geometric Mean | 2,686,271 | |
| Coefficient Of Variation | (99.54) | |
| Mean Deviation | 6,269,252 | |
| Median | (4,223,841) | |
| Standard Deviation | 7,293,016 | |
| Sample Variance | 53.2T | |
| Range | 20.3M | |
| R-Value | (0.94) | |
| Mean Square Error | 6.3T | |
| R-Squared | 0.89 | |
| Slope | (1,444,707) | |
| Total Sum of Squares | 797.8T |
Cyclo Net Income History
Other Fundumenentals of Cyclo Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cyclo Therapeutics Net Income component correlations
About Cyclo Therapeutics Financial Statements
Cyclo Therapeutics investors use historical fundamental indicators, such as Cyclo Therapeutics' Net Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cyclo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -18.1 M | -17.1 M | |
| Net Loss | -13.9 M | -13.2 M | |
| Net Loss | -17.5 M | -16.6 M | |
| Net Loss | (1.41) | (1.48) | |
| Net Income Per E B T | 1.14 | 1.51 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.